Introduction
Since the onset of the COVID-19 pandemic, concerns have persisted regarding the potential impact of SARS-CoV-2 on reproductive health. The virus enters cells via the ACE2 receptor and TMPRSS2 protease, both of which are expressed in human gametes and early embryos. This multicenter prospective cohort study investigates whether recent SARS-CoV-2 infection affects oocyte quality and early embryo development in couples undergoing in vitro fertilization (IVF).
Methods
This study was conducted across three reproductive centers in China between December 2022 and January 2023, involving 906 couples. Participants were divided into a COVID-19 group (n=206) and a non-COVID-19 group (n=700). The COVID-19 group was further stratified by the interval between female infection and oocyte retrieval: ≤7 days, 7–14 days, and >14 days. Laboratory outcomes, including oocyte maturation, fertilization (2PN zygotes), and day 3 embryo quality, were analyzed using multivariable linear regression to adjust for confounders such as age, BMI, and vaccination status.
Results
The study found that SARS-CoV-2 infection does not generally impair early-stage embryo quality. While the number of oocytes retrieved was similar between groups, the COVID-19 group showed a significantly higher number of 2PN zygotes (median 6.0 vs 5.0, P=0.021).
Subgroup analysis revealed that timing is a critical factor. Women infected within 7 days of oocyte retrieval exhibited a significant decrease in oocyte utilization rate (P=0.047 after adjustment). Interestingly, the 7–14 day group showed improved oocyte utilization and higher 2PN zygote counts compared to the non-COVID group, though this may be influenced by higher vaccination rates or small sample size (n=38). The rate of good-quality embryos on Day 3 remained statistically consistent across all groups (66.7% vs 69.2%).
Discussion
The findings suggest that while acute infection (within 7 days) may transiently affect oocyte competence, it is not a "dealbreaker" for IVF cycles. The lack of significant negative impact on embryo quality provides reassurance to patients and clinicians. However, the study is limited by its short-term scope, focusing only on Day 3 embryos, and the reliance on self-reported infection data. Future research is needed to determine if these early-stage results translate into successful live birth outcomes.
Conclusion
SARS-CoV-2 infection does not appear to have a broad negative impact on early embryonic development. While a very recent infection might slightly reduce oocyte utilization, overall embryo quality is maintained. This data-driven clarity suggests that aggressive cycle cancellations due to recent infection may not be necessary for early developmental outcomes.
Summary updated